Market Access Compared: Registration Logic in China, the US and the EU
The Three Markets at a Glance
| Market | Framework | Typical path for energy devices | Scale of time |
|---|---|---|---|
| China | NMPA classes I/II/III | Class II/III registration + QMS inspection | 2-4 years (Class III) |
| US | FDA classes I/II/III | Mostly 510(k) substantial equivalence | 90-day statutory review, years in practice |
| EU | MDR (notified bodies) | Class IIa/IIb certification + technical docs + CER | 1-2+ years |
Details in the dedicated entries: NMPA, 510(k), CE-MDR.
Key Differences
- Different philosophies: China front-loads risk-based approval; the US centers on equivalence to marketed devices; the EU centers on the manufacturer’s technical documentation and ongoing compliance.
- Different evidence centers: registration testing + clinical evaluation in China; predicate comparison + performance data in the US; CER and post-market surveillance in the EU.
- Converging holder duties: all three require QMS (13485 or equivalent) and post-market vigilance.
Using Registration as a Filter
- As a floor: unregistered-in-market devices don’t enter comparison, whatever the price.
- As progress signal: brands “in registration” must show acceptance/progress evidence for wait-risk assessment.
- As a quality proxy: passing strict markets correlates with mature systems (not absolute, but strong).
FAQ
Does CE open all EU countries?
Under MDR, broadly yes — but each country adds local requirements (language, importer registration, reimbursement). Local checks remain mandatory.
Which market to register first?
Rank by business scale: home market → largest export market → the rest. Fees and timelines stack — budget in years.